KR20150036592A - 백신 조성물 - Google Patents

백신 조성물 Download PDF

Info

Publication number
KR20150036592A
KR20150036592A KR20157003821A KR20157003821A KR20150036592A KR 20150036592 A KR20150036592 A KR 20150036592A KR 20157003821 A KR20157003821 A KR 20157003821A KR 20157003821 A KR20157003821 A KR 20157003821A KR 20150036592 A KR20150036592 A KR 20150036592A
Authority
KR
South Korea
Prior art keywords
gly
dengue
thr
leu
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR20157003821A
Other languages
English (en)
Korean (ko)
Inventor
알랜 보우케누헤
레미 포라
쟝 랑
멜라니 사빌
나디아 토니포쓰
Original Assignee
사노피 파스퇴르
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 사노피 파스퇴르 filed Critical 사노피 파스퇴르
Publication of KR20150036592A publication Critical patent/KR20150036592A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR20157003821A 2012-07-24 2013-07-24 백신 조성물 Ceased KR20150036592A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP12305907.3 2012-07-24
EP12305907 2012-07-24
EP12305912.3 2012-07-25
EP12305912 2012-07-25
PCT/EP2013/065667 WO2014016360A1 (en) 2012-07-24 2013-07-24 Vaccine compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020207016038A Division KR20200067938A (ko) 2012-07-24 2013-07-24 백신 조성물

Publications (1)

Publication Number Publication Date
KR20150036592A true KR20150036592A (ko) 2015-04-07

Family

ID=48875047

Family Applications (2)

Application Number Title Priority Date Filing Date
KR20157003821A Ceased KR20150036592A (ko) 2012-07-24 2013-07-24 백신 조성물
KR1020207016038A Ceased KR20200067938A (ko) 2012-07-24 2013-07-24 백신 조성물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020207016038A Ceased KR20200067938A (ko) 2012-07-24 2013-07-24 백신 조성물

Country Status (11)

Country Link
US (2) US20150196631A1 (https=)
EP (2) EP2877208B1 (https=)
JP (2) JP2015524421A (https=)
KR (2) KR20150036592A (https=)
CN (1) CN104812407B (https=)
AU (1) AU2013295014B2 (https=)
MX (2) MX381497B (https=)
MY (2) MY197723A (https=)
PH (1) PH12014502840B1 (https=)
SG (2) SG10201912291YA (https=)
WO (1) WO2014016360A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013295016A1 (en) * 2012-07-24 2015-01-29 Sanofi Pasteur Vaccine compositions for prevention against dengue virus infection
EP2968516B1 (en) 2013-03-15 2022-01-12 Takeda Vaccines, Inc. Compositions and methods for dengue virus chimeric constructs in vaccines
TWI852899B (zh) 2014-09-02 2024-08-21 法商賽諾菲巴斯德公司 疫苗組合物
WO2016130321A1 (en) * 2015-02-09 2016-08-18 Academia Sinica An epitope-substituted vaccine for use in improving safety and immunogenicity against dengue viruses
EP3316905A1 (en) * 2015-07-03 2018-05-09 Sanofi Pasteur Concomitant dengue and yellow fever vaccination
EP3147294B1 (en) * 2015-09-24 2020-04-29 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Distinguishing dengue virus infections from other flaviviral infections using a recombinant mutant envelope protein
KR102373570B1 (ko) * 2015-11-27 2022-03-10 케이엠 바이올로직스 가부시키가이샤 뎅기 바이러스 약독주를 뱅크화한 생바이러스, 및 그것들을 항원으로 하는 뎅기 백신
JP2019511533A (ja) * 2016-04-13 2019-04-25 タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. 小児及び若年成人のデングウイルスに対するワクチンの組成物及び方法
US11531029B2 (en) 2017-05-08 2022-12-20 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Methods and compositions for the detection of flavivirus infections
WO2019069130A1 (en) * 2017-10-05 2019-04-11 Sanofi Pasteur COMPOSITIONS FOR RECALL VACCINATION AGAINST DENGUE
US11491217B2 (en) 2017-12-06 2022-11-08 Emory University Chimeric viruses encoding mutant zika virus envelope glycoproteins
EP3549603A1 (en) 2018-04-06 2019-10-09 Sanofi Pasteur Live-attenuated yellow fever virus strain adapted to grow on vero cells and vaccine composition comprising the same
EP3846849A1 (en) 2018-09-05 2021-07-14 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
US11426461B2 (en) 2018-09-05 2022-08-30 Takeda Vaccines, Inc. Methods for preventing dengue and hepatitis A
US11464815B2 (en) 2018-09-05 2022-10-11 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
CN112079934B (zh) * 2019-12-17 2021-01-29 合源生物科技(天津)有限公司 一种靶向cd19的嵌合抗原受体及其用途
CN116334070B (zh) * 2023-02-15 2026-02-06 天津大学 融合蛋白的应用和细胞融合的方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5422A (en) 1848-02-01 Spark-arrester
US109A (en) 1836-12-15 Erawijtg
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
FR2649012B1 (fr) 1989-07-03 1991-10-25 Seppic Sa Emulsions multiphasiques injectables
FR2649013B1 (fr) 1989-07-03 1991-10-25 Seppic Sa Vaccins et vecteurs de principes actifs fluides contenant une huile metabolisable
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6254873B1 (en) 1995-04-17 2001-07-03 The United States Of America As Represented By The Secretary Of The Army Inactivated dengue virus vaccine
WO1996040933A1 (en) 1995-06-07 1996-12-19 The Government Of The United States Of America, Represented By The Secretary Department Of Health And Human Services Infectious dengue 2 virus pdk-53 as quadravalent vaccine
EP0977587B1 (en) 1997-02-28 2005-06-15 Acambis Inc. Chimeric flavivirus vaccines
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
AU1145699A (en) 1997-09-05 1999-03-22 Smithkline Beecham Biologicals (Sa) Oil in water emulsions containing saponins
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
WO2000057909A2 (en) 1999-03-26 2000-10-05 Walter Reed Army Institute Of Research Attenuated dengue-2 virus vaccine
CA2368790A1 (en) 1999-03-26 2000-10-05 Walter Reed Army Institute Of Research Attenuated dengue-3 virus vaccine
US6537557B1 (en) 1999-03-26 2003-03-25 The United States Of America As Represented By The Secretary Of The Army Attenuated dengue-4 virus vaccine
JP2002540169A (ja) 1999-03-26 2002-11-26 ウォルター リード アーミー インスティテュート オブ リサーチ 弱毒化デング熱１型ウイルスワクチン
ATE526411T1 (de) 2000-02-16 2011-10-15 Us Gov Health & Human Serv Avirulente, immunogene flavivirus-chimäre
ATE412738T1 (de) 2000-05-30 2008-11-15 Univ Mahidol Attenuierte stammen von denguevirus und ihre verwendungen in impfstoffzusammensetzungen
AT410634B (de) 2001-02-21 2003-06-25 Franz X Dr Heinz Attenuierte lebendimpfstoffe
CA2966716C (en) 2001-05-22 2019-11-26 The Government Of The United States Of America, As Represented By The Cretary, Department Of Health And Human Services Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses
WO2002095007A2 (en) 2001-05-23 2002-11-28 Dendreon San Diego Llc Conjugates activated by cell surface proteases and therapeutic uses thereof
CN1551782A (zh) 2001-06-01 2004-12-01 ��������ķ������ 嵌合黄病毒载体
KR101074175B1 (ko) * 2002-01-15 2011-10-14 사노피 파스테르 바이오로직스 씨오 플라비바이러스 백신
US20040259224A1 (en) * 2002-05-31 2004-12-23 Farshad Guirakhoo Tetravalent Dengue vaccines
CA2611954C (en) 2005-06-17 2014-01-28 Sanofi Pasteur Dengue serotype 2 attenuated strain
CN101238144B (zh) * 2005-06-17 2012-09-05 赛诺菲巴斯德有限公司 登革血清型1减毒株
AR054822A1 (es) 2005-07-07 2007-07-18 Sanofi Pasteur Emulsion inmuno adyuvante
JP5227172B2 (ja) 2005-08-10 2013-07-03 サノフィ パスツール バイオロジクス リミテッド ライアビリティ カンパニー デングウイルス感染に対するワクチン接種
KR101357685B1 (ko) * 2005-11-21 2014-02-06 사노피 파스퇴르 리미티드 / 사노피 파스퇴르 리미떼 재조합 바이러스용 안정화 제형
US7968102B2 (en) * 2006-01-13 2011-06-28 Sanofi Pasteur S.A. Dengue chimeric viruses
FR2896162B1 (fr) 2006-01-13 2008-02-15 Sanofi Pasteur Sa Emulsion huile dans eau thermoreversible
FR2903605A1 (fr) 2006-07-12 2008-01-18 Sanofi Pasteur Sa Methode d'immunisation contre les quatres serotypes de la dengue
FR2906724B1 (fr) * 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
FR2909286B1 (fr) 2006-12-01 2012-06-08 Sanofi Pasteur Methode d'immunisation contre les 4 serotypes de la dengue
EP2143440A1 (fr) 2008-07-09 2010-01-13 Sanofi Pasteur Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués
GB201007531D0 (en) 2010-05-05 2010-06-23 Imp Innovations Ltd Composition

Also Published As

Publication number Publication date
KR20200067938A (ko) 2020-06-12
AU2013295014B2 (en) 2018-01-18
EP3932422A1 (en) 2022-01-05
MX381497B (es) 2025-03-12
MX2015000442A (es) 2015-03-12
MY168959A (en) 2019-01-28
PH12014502840A1 (en) 2015-02-23
US20150196631A1 (en) 2015-07-16
EP2877208B1 (en) 2021-05-12
EP2877208A1 (en) 2015-06-03
PH12014502840B1 (en) 2015-02-23
SG10201912291YA (en) 2020-02-27
WO2014016360A1 (en) 2014-01-30
MY197723A (en) 2023-07-10
CA2878682A1 (en) 2014-01-30
AU2013295014A1 (en) 2015-01-29
HK1212906A1 (zh) 2016-06-24
JP6830118B2 (ja) 2021-02-17
JP2015524421A (ja) 2015-08-24
CN104812407A (zh) 2015-07-29
JP2019151636A (ja) 2019-09-12
SG11201500412TA (en) 2015-02-27
US20190201517A1 (en) 2019-07-04
CN104812407B (zh) 2022-11-22
MX2021004211A (es) 2021-05-27

Similar Documents

Publication Publication Date Title
JP6830118B2 (ja) ワクチン組成物
KR20150036593A (ko) 뎅기열 바이러스 감염 예방용 백신 조성물
US8088391B2 (en) West nile virus vaccine
JP5227172B2 (ja) デングウイルス感染に対するワクチン接種
US10946087B2 (en) Vaccine compositions against dengue virus diseases
WO2014083194A1 (en) Methods for inducing antibodies
CA2878682C (en) Vaccine compositions for use in a method of protecting a human subject against dengue disease
HK1212906B (en) Vaccine compositions
BR112015001145B1 (pt) Composição de vacina para uso em um método de proteção de um indivíduo humano contra a doença da dengue, kit compreendendo a mesma e seu uso

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20150212

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20180724

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20191015

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20200224

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20191015

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20200224

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20191211

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20180724

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20200403

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20200326

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20200224

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20191211

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20191015

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20180724

X601 Decision of rejection after re-examination
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20200604